検索結果 - Jon Arnason

結果の絞り込み
  1. 1
    Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition

    Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition 著者: Maud Condomines, Jon Arnason, Reuben Benjamin, Gertrude Gunset, Jason Plotkin, Michel Sadelain

    出版事項 2015
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  2. 2
    Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025

    Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025 著者: Gena Kanas, Wenzhen Ge, Ruben G.W. Quek, Katie Keeven, Knar Nersesyan, Jon Arnason

    出版事項 2021
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  3. 3
    Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years

    Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years 著者: Alison M. Schram, Paige Comstock, Meghan Campo, Daniel Gorovets, Ann Mullally, Kelly Bodio, Jon Arnason, Nancy Berliner

    出版事項 2015
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    Assessing Unwanted Variations in Rheumatology Clinic Previsit Rooming

    Assessing Unwanted Variations in Rheumatology Clinic Previsit Rooming 著者: Edmond Ramly, Brad Stroik, Diane Lauver, Heather M. Johnson, Patrick E. McBride, Kristin Lewicki, Jón Árnason, Christie M. Bartels

    出版事項 2018
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  5. 5
    Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease

    Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease 著者: Katharina Lahl, Christoph Loddenkemper, Cathy E. Drouin, Jennifer Freyer, Jon Arnason, Gérard Eberl, Alf Hamann, Hermann Wagner, Jochen Huehn, Tim Sparwasser

    出版事項 2007
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma

    Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma 著者: Jeremy S. Abramson, Jon Arnason, Ann S. LaCasce, Robert Redd, Jeffrey A. Barnes, Lubomir Sokol, Robin Joyce, David Avigan, Donna Neuberg, Ronald W. Takvorian, Ephraim P. Hochberg, Celeste M. Bello

    出版事項 2019
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  7. 7
    Lenalidomide enhances anti-myeloma cellular immunity

    Lenalidomide enhances anti-myeloma cellular immunity 著者: Katarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills, Dina Stroopinsky, Turner Kufe, Baldev Vasir, Jon Arnason, D. Tzachanis, Jeffrey I. Zwicker, Robin Joyce, James D. Levine, Kenneth C. Anderson, Donald Küfe, David Avigan

    出版事項 2012
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  8. 8
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL 著者: Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, K. OGASAWARA, Jerill Thorpe, William G. Wierda

    出版事項 2021
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  9. 9
    MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

    MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells 著者: Dina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, Heidi Mills, Li Yin, Hasan Rajabi, Baldev Vasir, Turner Kufe, Katarina Luptakova, Jon Arnason, Caterina Nardella, James D. Levine, Robin Joyce, Ilene Galinsky, Yoram Reiter, Richard M. Stone, Pier Paolo Pandolfi, Donald Küfe, David Avigan

    出版事項 2013
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  10. 10
    Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study

    Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study 著者: Matthew S. Davids, Haesook T. Kim, Alyssa Nicotra, Alexandra Savell, Karen Francoeur, Jeffrey Hellman, Josie Bazemore, Hari P. Miskin, Peter Sportelli, Laura Stampleman, Rodrigo Maegawa, Jens Rueter, Adam Boruchov, Jon Arnason, Caron A. Jacobson, Eric D. Jacobsen, David C. Fisher, Jennifer R. Brown

    出版事項 2018
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  11. 11
    Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

    Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL) 著者: Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Ana Kostić, Yeonhee Kim, K. OGASAWARA, Christine Dehner, Tanya Siddiqi

    出版事項 2021
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  12. 12
    Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

    Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study 著者: Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, K. OGASAWARA, Manali Kamdar

    出版事項 2022
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  13. 13
    Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

    Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001 著者: Maria Lia Palomba, Leo I. Gordon, Tanya Siddiqi, Jeremy S. Abramson, Manali Kamdar, Matthew A. Lunning, David G. Maloney, Charalambos Andreadis, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Scott R. Solomon, Thalia A. Farazi, Jacob Garcia, Christine Dehner, K. OGASAWARA, Jie Gao, Michael Wang

    出版事項 2020
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  14. 14
    Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

    Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas 著者: Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina Albertson, Jacob Garcia, Ana Kostić, D. Li, Yeonhee Kim, Tanya Siddiqi

    出版事項 2019
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  15. 15
    Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

    Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity 著者: Benjamin L. Lampson, Siddha Kasar, Tiago R. Matos, Elizabeth A. Morgan, Laura Z. Rassenti, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Caron A. Jacobson, Philippe Armand, Jeremy S. Abramson, Jon Arnason, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John Hanna, Jerome Ritz, Haesook T. Kim, Jennifer R. Brown

    出版事項 2016
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  16. 16
    Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

    Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patie... 著者: Rajat Bannerji, John N. Allan, Jon Arnason, Jennifer R. Brown, Ranjana H. Advani, Stephen M. Ansell, Susan O’Brien, Johannes Duell, Peter Martin, Robin Joyce, Jingjin Li, Dina M. Flink, Min Zhu, David M. Weinreich, George D. Yancopoulos, Andres Sirulnik, Aafia Chaudhry, Srikanth R. Ambati, Max S. Topp

    出版事項 2020
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  17. 17
    Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

    Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort i... 著者: Rajat Bannerji, Jon Arnason, Ranjana H. Advani, Jennifer R. Brown, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Susan O’Brien, Julio C. Chávez, Johannes Duell, Andreas Rosenwald, Jennifer L. Crombie, Melanie Ufkin, Jingjin Li, Min Zhu, Srikanth R. Ambati, Aafia Chaudhry, Israel Lowy, Max S. Topp

    出版事項 2022
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  18. 18
    Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

    Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial 著者: Jennifer R. Brown, Mehdi Hamadani, John Hayslip, Ann Janssens, Nina D. Wagner‐Johnston, Oliver G. Ottmann, Jon Arnason, Hervé Tilly, Michael Millenson, Fritz Offner, Nashat Gabrail, Siddhartha Ganguly, Sikander Ailawadhi, Siddha Kasar, Arnon P. Kater, Jeanette K. Doorduijn, Lei Gao, Joanne Lager, Bin Wu, Coumaran Égile, Marie José Kersten

    出版事項 2018
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  19. 19
    Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

    Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autolo... 著者: Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, David G. Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, K. OGASAWARA, Timothy R. Mack, Jeremy S. Abramson

    出版事項 2021
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  20. 20
    MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

    MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia 著者: Athalia R. Pyzer, Dina Stroopinsky, Hasan Rajabi, Abigail Washington, Ashujit Tagde, Maxwell Coll, Jacqueline Fung, Mary Paty Bryant, Leandra Cole, Kristen Palmer, Poorvi Somaiya, Rebecca Karp Leaf, Myrna Nahas, Arie Apel, Salvia Jain, Malgorzata McMasters, Lourdes M. Mendez, James D. Levine, Robin Joyce, Jon Arnason, Pier Paolo Pandolfi, Donald Küfe, Jacalyn Rosenblatt, David Avigan

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: